Magnetosensitive polyfunctional nanocomposites on the basis of magnetite and hydroxyapatite for their use in oncology

  • M. V. Abramov O.O. Chuiko Institute of Surface Chemistry, National Academy of Sciences of Ukraine
  • A. L. Petranovska O.O. Chuiko Institute of Surface Chemistry, National Academy of Sciences of Ukraine
  • Ye. V. Pylypchuk O.O. Chuiko Institute of Surface Chemistry, National Academy of Sciences of Ukraine
  • S. P. Turanska O.O. Chuiko Institute of Surface Chemistry, National Academy of Sciences of Ukraine
  • N. M. Opanashchuk O.O. Chuiko Institute of Surface Chemistry, National Academy of Sciences of Ukraine
  • N. V. Kusyak Ivan Franko Zhytomyr State University
  • S. V. Gorobets National Technological University of Ukraine “Kyiv Polytechnic Institute after Igor Sikorskiy”
  • P. P. Gorbyk O.O. Chuiko Institute of Surface Chemistry, National Academy of Sciences of Ukraine
Keywords: hydroxyapatite, surface, magnetite, magnetically sensitive nanocomposites, adsorption

Abstract

The results of the research directed at the development of the concept of creating the magneto-sensitive nanocomposites (NC) with multilayered hierarchic nano-architecture of a core-shell type as well as with functions of biomedical nano-robots on the basis of a single-domain magnetite (Fe3O4), whose surface is modified by hydroxyapatite (HA) have been systemized and generalized. The nanostructures of this type are characterized by bio-adaptability with a person’s organism, deficiency of mutagenicity as well as by satisfactory magnetic characteristics from the point of view of the realization of the method of address delivery of medicines and local therapy.

 Fe3O4 has been synthesized according to the method of neutralizing the salts of 2- and 3-valent Ferrum. The synthesized assemblages of nanoparticles (NP) of Fe3O4 were characterized by the limits of 3-23 nm. The average size of NP of Fe3O4 depended on synthesis conditions and equaled 8-15nm, the distribution according to their size could be done using technological methods. The specific surface of the magnetite was S = 90–180 м2/g, the samples for which S= ~ 110 м2 /g were used in process. By means of IR –spectra studies of the Fe3O4 surface, were discovered some functional groups of OH, the concentration of which was calculated on the data of thermo-gravimetric analysis and equaled 2.4 mM/g.

The synthesis of HA membrane on Fe3O4 surface was performed using sol-gel method. The average crystals size of Fe3O4 and HA in the structure of NC Fe3O4/HA respectively equaled 15 and 19-21nm. By means of IR- spectra studies of Fe3O4/HA samples, groups of OH were discovered on the NC surface, their concentration was 2.2mM/g. The specific surface of NC Fe3O4 equaled Sп = 105 м2/g. Ca/P ratio was 1.6-1.7. The HA thickness on the Fe3O4 surface was estimated on Fe2p-/Fe3p-lines area to NC mass gain ratio and equaled ~4 nm.

The processes of adsorption immobilization of chemotherapeutic preparations (cisplatin (CP), doxorubicin (DR)) as well as of normal immune globulin of a man (as a model of antibody-immune-therapeutic preparation) on NC surface have been studied. 

Some significant adsorption activity related to CP complexes of nano-sized Fe3O4 has been discovered. Thus, under 298K for Fe3O4 the adsorption capacity Аmax = 80,1 mg/g, the removal coefficient R = 66,2 %.

Fe3O4 modification by HA reduces the adsorption activity of NC surface related to CP:  Аmax = 54 mg/g, R = 64,8%. Perhaps, it occurs due to the decrease in the concentration of hydroxyl groups on NC surface of Fe3O4/HA as compared to the surface of initial Fe3O4. The period for establishing the absorption balance for NC surface of Fe3O4 /HA is within 10 min.

The immune- globulin adsorption(Ig) was taking place in the medium of sodium chloride solution (SCS) for two hours in a dynamic regime under indoor temperature. The amount of adsorbed substance on the NC surface was determined by measuring the concentration of Ig in contact solutions before and after adsorption.

The emitting of Ig in SCS was studied on Fe3O4/HА and on Fe3O4/HА/Ag samples which contain Ig immobilized from different buffer systems (phosphate buffer, physiological solution).

The distribution coefficient (E) of immune globulin between the NC surface and the solution is 111,36 ml/g for Fe3O4/HА, and 186.67 ml/g for Fe3O4/HА/Ag. Under the adsorption from SCS for Fe3O4/HА Ε = 47, 2 ml/g, for Fe3O4/HА/Ag Е = 59,4 ml/g.

The adsorption of Ig on the surface of NC from silver NP exceeds the adsorption on the surface of Fe3O4/HA in both buffer systems. It testifies to the fact that silver nano particles on the surface of a composite serve as additional adsorption centers.

It has been determined that Ig emitting immobilized from SCS under high concentrations (A=17.38mg/g) practically does not occur. 

The results of the experimental studies as to the NC effects on the cells lines MCF-7 of breast carcinoma of a man in vitro testify to the fact that the use of multifunctional magneto-sensitive NC allows to recognize specific cells, to achieve cytotoxic effect of the preparation under lower concentrations of medicines as well as to create conditions for reducing toxic and allergic effects of medical chemotherapeutic products on the organism as a whole.    

By the studies of DR adsorption on the surface of NC Fe3O4/HA it has been determined that during the first two hours 60 - 70% of the substance is adsorbed, and during the period of 24 hours 93 - 97% is adsorbed. The results of the studies as to the dependence of desorption on time indicate that DR emitting decreases when its amount increases on the NC surface. 

The research has submitted the data as to synthesis of new multifunctional magneto-sensitive nanostructures which are prospective for a directed delivery of medicine with chemotherapeutic mechanism of action gemcitabine (GC) into the tumors of hepatocellular carcinoma and intrahepatic cholangiocarcinoma as well as for hypothermic therapy and magnetic resonance optical tomography diagnostics by means of magnetic field with additional functions and in a regime of real time. 

It has been shown that modified by HA surface of magneto-sensitive carriers of Fe3O4 is capable of adsorption mobilization of oncological medicines with different mechanisms of action as well as of their emitting into the medium of body fluid without therapeutic activity changes.  

 On the example of a magnetic fluid Fe3O4/HA/DR/ ol.Na/PEG+SCS, which contains a dispersion phase - sodium chloride solution (SCS), superparamagnetic carriers of Fe3O4 with a modified by HA surface and with a immobilized medicine DR, a complex stabilizer on the basis of sodium oleate and polyethylene glycol (ol.Na/PEG), the method of magnetic granulometry has been schemed out. This method can be applied to NC of super magnetic nuclear-membrane type with a complex multilayered structure.

The results of the experimental studies and of calculations, as well as their checking and comparing with literature data, testify to the fact that by using both the assemblages of magneto carriers acting as a super magnetic probe and Lanzheven’s theory of paramagnetism, we can estimate the components size of a complex shell-type nanocomposites structure. The obtained results can be useful when improving the chemical composition, structure and the qualities of new magnetic fluids and adsorbing agents on the basis of magneto-sensitive NC with a complex membrane structure. 

New scientific approaches as to the introduction of magneto-sensitive polyfunctional NC of Fe3O4/HA, modified by the ions of gadolinium into neutron capture therapy have been practiced. The prospective for the creation of new types of low- toxic selective neutron- capture medicines with additional functions of magneto-sensitive direct delivery to organs or target cells and for deposition, hyperthermia and complex T1-, T2-MRT diagnostic testing in a real time regime, has been shown.

The basis for synthesis of new vector systems - magneto-sensitive drug formulations of chemotherapeutic action for cancer care on the basis of magneto fluids which contain nano-sized single-domain magnetite with a modified surface as well as cytostatic drug has been presented. It has been shown that according to the data of magnetic measurements the size parameters of vector systems can be accurately determined, it can be used for their standardization and parameters control in the productive process.

References

1. Levy L., Sahoo Y., Kyoung-Soo Kim, Earl Bergey J., Prasad P. Synthesis and characterization of multifunctional nanoclinics for biological applications. Chem. Mater. 2002. 14(9): 3715. https://doi.org/10.1021/cm0203013

2. Shpak A.P., Gorbyk P.P. Physical chemistry of nanomaterials and supramolecular structures. (Kyiv: Naukova Dumka, 2007). [in Russian].

3. Shpak A.P., Gorbyk P.P. Nanomaterials and Supramolecular Structures: Physics, Chemistry, and Applications. (Springer, 2009).

4. Patent UA 99211. Gorbyk P.P., Petanovskaya A.L., Turelik M.P., Turanska S.P., Vasilieva O.A., Chekhun V.F., Lukyanova N.U., Shpak A.P., Korduban O.M. Nanocapsule with functions of nanorobot. 2012. [in Ukrainian].

5. Gorbyk P.P., Chekhun V.F. Nanocomposites of medicobiologic destination: reality and perspectives for oncology. Funct. Mater. 2012. 19(2): 145.

6. Gorbyk P.P. Nanocomposites with Functions of Biomedical Nanorobots: Synthesis, Properties, Application. Nanosystems, Nanomaterials, Nanotechnologies. 2013. 11(2): 323. [in Ukrainian].

7. Gorbyk P.P., Lerman L.B., Petranovska A.L., Turanska S.P. Magnetosensitive nanocomposites with functions of medico-biological nanorobots: Synthesis and properties. In: Advances in Semiconductor Research: Physics of Nanosystems, Spintronics and Technological Applications. 2014. P. 161.

8. Gorbyk P.P., Lerman L.B., Petranovska A.L., Turanska S.P., Pylypchuk Ie.V. Magnetosensitive nanocomposites with hierarchical nanoarchitecture as biomedical nanorobots: synthesis, properties, and application. Fabrication and Self-Assembly of Nanobiomaterials, Applications of Nanobiomaterials. V. 1. 2016. P. 289.

9. Wahajuddin S.A. Superparamagnetic iron oxide nanoparticles: magnetic nanoplatforms as drug carriers. Int. J. Nanomedicine. 2012. 7: 3445. https://doi.org/10.2147/IJN.S30320

10. Huang C., Zhou Y., Tang Z., Guo X., Qian Z., Zhou S. Synthesis of multifunctional Fe3O4 core/hydroxyapatite shell nanocomposites by biomineralization. Dalton Trans. 2011. 40(18): 5026. https://doi.org/10.1039/c0dt01824d

11. Tomohiro Iwasaki. Mechanochemical synthesis of magnetite/hydroxyapatite nanocomposites for hyperthermia. Materials Science - Advanced Topics. 2013. P. 175. https://doi.org/10.5772/54344

12. Gopi D., Thameem Ansari M., Shinyjoy E., Kavitha L. Synthesis and spectroscopic characterization of magnetic hydroxyapatite nanocomposite using ultrasonic irradiation. Spectrochim. Acta. Part A. 2012. 87: 245. https://doi.org/10.1016/j.saa.2011.11.047

13. Mir A., Mallik D., Bhattacharyya S., Mahata D., Sinha A., Nayar S. Aqueous ferrofluids as templates for magnetic hydroxyapatite nanocomposites. J. Mater. Sci. - Mater. Med. 2010. 21(8): 2365. https://doi.org/10.1007/s10856-010-4090-9

14. Feng C., Chao L., Ying-Jie Z., Xin-Yu Zhao, Bing-Qiang L., Jin W. Magnetic nanocomposite of hydroxyapatite ultrathin nanosheets/Fe3O4 nanoparticles: microwave-assisted rapid synthesis and application in pH-responsive drug release. Biomater. Sci. 2013. 1(10): 1074. https://doi.org/10.1039/c3bm60086f

15. Davaran S., Alimirzalu S., Nejati-Koshki K., Nasrabadi H.T., Akbarzadeh A., Khandaghi A.A., Abbasian M., Alimohammadi S. Physicochemical characteristics of Fe3O4 magnetic nanocomposites based on poly(N-isopropylacrylamide) for anti-cancer drug delivery. Asian Pac. J. Cancer Prev. 2014. 15(1): 49. https://doi.org/10.7314/APJCP.2014.15.1.49

16. Petranovska A.L., Abramov N.V., Turanska S.P., Gorbyk P.P., Kaminskiy A.N., Kusyak N.V. Adsorption of cis-dichlorodiammineplatinum by nanostructures based on single-domain magnetite. J. Nanostruct. Chem. 2015. 5(3): 275. https://doi.org/10.1007/s40097-015-0159-9

17. Abramov N.V., Turanska S.P., Kusyak A.P., Petranovska A.L., Gorbyk P.P. Synthesis and properties of magnetite/hydroxyapatite/doxorubicin nanocomposites and magnetic fluids based on them. J. Nanostruct. Chem. 2016. 6: 223. https://doi.org/10.1007/s40097-016-0196-z

18. Anirudhan T.S., Sandeep S. Synthesis, characterization, cellular uptake and cytotoxicity of a multi-functional magnetic nanocomposite for the targeted delivery and controlled release of doxorubicin to cancer cells. J. Mater. Chem. 2012. 22(25): 12888. https://doi.org/10.1039/c2jm31794j

19. Sadighian S., Hosseini-Monfared H., Rostamizadeh K., Hamidi M. pH-Triggered magnetic-chitosan nanogels (MCNs) for doxorubicin delivery: physically vs. chemically cross linking approach. Adv. Pharm. Bull. 2015. 5(1): 115.

20. Borisenko N.V., Bogatyrev V.M., Dubrovin I.V., Abramov N.V., Gaevaya M.V., Gorbyk P.P. Synthesis and properties of magnetically sensitive nanocomposites based on iron and silicon oxides. Physical chemistry of nanomaterials and supramolecular structures. 2007. 1: 394. [in Russian].

21. Turanska S.P., Kusyak A.P., Petranovskaya A.L., Gorobets S.V., Turov V.V., Gorbyk P.P. Cytotoxic activity of magnetoerated nanocomposites on the basis of doxorubicin on the example of Saccharomyces serevisiae. Him. Fiz. Tehnol. Poverhni. 2016. 7(2): 236. [in Ukrainian]. https://doi.org/10.15407/hftp07.02.236

22. Wagner C.D., Moulder J.F., Davis L.E., Riggs W.M. Handbook of X-ray Photoelectron Spectroscopy. (New York: Perking-Elmer Corp., 1979).

23. Abramov M.V., Kusyak A.P., Kaminsky O.M., Turanska S.P., Petranovskaya A.L., Kusyak N.V., Turov V.V., Gorbyk P.P. Synthesis and properties of magnetically sensitive polyfunctional nanocomposites for use in oncology. Surface. 2017. 9(24): 165. [in Ukrainian]. https://doi.org/10.15407/Surface.2017.09.165

24. Skvortsov A.N. Effective method of analyzing the spectra of the optical range in studies of the kinetics of reactions. Cytology. 2009. 51(3): 229. [in Russian].

25. Raghavan R., Cheriyamundath S., Madassery J. Dimethyl sulfoxide inactivates the anticancer effect of cisplatin against human myelogenous leukemia cell lines in in vitro assays. Indian J. Pharmacol. 2015. 47(3): 322. https://doi.org/10.4103/0253-7613.157132

26. Silva P.P., de Paula F.C.S., Guerra W., Silveira J.N., Botelho F.V., Vieira L.Q., Bortolotto T., Fischer F.L., Bussi G., Terenzi H., Pereira-Maia E.C. Platinum(II) compounds of tetracyclines as potential anticancer agents: cytotoxicity, uptake and interactions with DNA. J. Braz. Chem. Soc. 2010. 21(7). https://doi.org/10.1590/S0103-50532010000700011

27. Gorbyk P.P., Turov V.V. Nanomaterials and nanocomposites in medicine, biology, ecology. (Kiev: Nauk. Dumka, 2011). [in Russian].

28. Bruijnincx P.C., Sadler P.J. New trends for metal complexes with anticancer activity. Curr. Opin. Chem. Biol. 2008. 12(2): 197. https://doi.org/10.1016/j.cbpa.2007.11.013

29. Patent UA 112490 Chekhun V.F., Lukyanova N.Yu., Gorbyk P.P., Todor I.M., Petranovskaya A.L., Boshitskaya N.V., Bozhko I.V. Antitumor ferromagnetic nanocomposite. 2016. [in Ukrainian].

30. Shen X., Liang H., Guo J. H., Song C. J. Inorg. Biochem. 2003. 95(2–3): 124. https://doi.org/10.1016/S0162-0134(03)00094-1

31. Gorbyk P.P., Mishchenko V.N., Petranovska A.L. Nanosystems, nanomaterials, nanotechnology. (Kyiv: RVV IMF, 2009). [in Ukrainian].

32. Turanskaya S.P., Chetyrkin A.D., Dubrovin I.V., Turov V.V., Gorbyk P.P. Synthesis, Properties, and Application in Experimental Medicine and Biology of Magnetosensitive Nanocomposites Containing Noble Metals. Surface. 2011. 3(18): 343. [in Russian].

33. Hermanson G.T. Bioconjugate Technigues. (Academic Press, 2008).

34. Doxorubicin hydrochloride. European Pharmacopoeia. Sixth Edition. 2005. P. 1389.

35. Biswanath Kundu, Debasree Ghosh, Mithlesh Kumar Sinha, Partha Sarathi Sen, Vamsi Krishna Balla, Nirmalendu Das, Debabrata Basu. Doxorubicin-intercalated nano-hydroxyapatite drug-delivery system for liver cancer: An animal model. Ceramics International. 2013. 39(8): 9557. https://doi.org/10.1016/j.ceramint.2013.05.074

36. Kule C., Ondrejickova O., Verner K. Doxorubicin, daunorubicin, and mitoxantrone cytotoxicity in yeast. Mol. Pharmacol. 1994. 46(6): 1234.

37. Patel S., Sprung A.U., Keller B.A., Heaton V.J., Fisher L.M. Identification of yeast DNA topoisomerase II mutants resistant to the antitumor drug doxorubicin: implications for the mechanisms of doxorubicin action and cytotoxicity. Mol. Pharmacol. 1997. 52(4):  658.https://doi.org/10.1124/mol.52.4.658

38. Saenko Yu.V., Shutov A.M., Rastorgueva E.V. Doxorubicin and menadione cause delay in cell proliferation of Saccharomyces cerevisiae by various mechanisms. Cytology. 2010. 52(5): 407. [in Russian].

39. Babayeva I.P., Chernov I.Yu. Biology of yeast. (KMK, 2004). [in Russian].

40. Mornet S., Vasseur S., Grasset F., Veverka P., Goglio G., Demourgues A., Portier J., Pollert E., Duguet E. Magnetic nanoparticle design for medical applications. Prog. Solid. State Chem. 2006. 34(2–4): 237. https://doi.org/10.1016/j.progsolidstchem.2005.11.010

41. Abramov N.V., Gorbyk P.P. Properties of magnetite nanoparticle ensembles and magnetic fluids for use in oncotherapy. Surface. 2012. 4(19): 246. [in Russian].

42. Abramov N.V. Doxorubicin-based magnetic fluids for use in oncotherapy. Surface. 2014. 6(21): 241. [in Russian].

43. Chen D.-X., Sun N., Gu H.-C. Size analysis of carboxydextran coated superparamagnetic iron oxide particles used as contrast agents of magnetic resonance imaging. J. Appl. Phys. 2009. 106(6): 063906.  https://doi.org/10.1063/1.3211307

44. Kaiser R., Miscolezy G. Magnetic properties of staible dispertions of subdomain magnetic particles. J. Appl. Phys. 1970. 1(3): 1064. https://doi.org/10.1063/1.1658812

46. Thakur M., De K., Giri S., Si S., Kotal A., Mandal T.K. Interparticle interaction and size effect in polymer coated magnetite nanoparticles. Journal of Physics: Condensed Matter. 2006. 18(39): 9093. https://doi.org/10.1088/0953-8984/18/39/035

47. Biswanath Kundu, Debasree Ghosh, Mithlesh Kumar Sinha, Partha Sarathi Sen, Vamsi Krishna Balla, Nirmalendu Das, Debabrata Basu. Doxorubicin-intercalated nano-hydroxyapatite drug-delivery system for liver cancer: An animal model. Ceram. Int. 2013. 39(8): 9557. https://doi.org/10.1016/j.ceramint.2013.05.074

48. Frolov Yu.G. Course of colloid chemistry. (Moscow: Chemistry, 1989.) [in Russian].

49. Schliomis M.I. Magnetic fluids. UFN. 1974. 112(3): 427. [in Russian]. https://doi.org/10.3367/UFNr.0112.197403b.0427

50. Rosenzweig R. Ferrohydrodynamics. (Moscow: Mir, 1989). [in Russian].

51. Bellin M.F. MR Contrast Agents, the Old and the New. Eur. J. Radiol. 2006. 60: 314. https://doi.org/10.1016/j.ejrad.2006.06.021

52. Caravan P. Strategies for Increasing the Sensitivity of Gadolinium Based MRI Contrast Agents. Chem. Soc. Rev. 2006. 35(6): 512. https://doi.org/10.1039/b510982p

53. Lowe M.P. MRI Contrast Agents: the next generation. Aust. J. Chem. 2002. 55(9): 551. https://doi.org/10.1071/CH02172

54. Fukumori Y., Ichikawa H. Nanoparticles for Cancer Therapy and Diagnosis. Adv. Powder. Technol. 2006. 17(1): 1. https://doi.org/10.1163/156855206775123494

55. Pylypchuk Ye.V., Gorbyk P.P. B- and Gd-containing nanomaterials and nanocomposites for neutron capture therapy. Surface. 2014. 6(21): 150. [in Ukrainian].

56. Gorbyk P.P., Petranovskaya A.L., Pylypchuk Ye.V., Abramov N.V., Oranskaya E.I., Korduban A.M. Synthesis of magnetically sensitive Gd-containing nanostructures. Him. Fiz. Tehnol. Poverhni. 2011. 2(4): 385. [in Russian].

57. Pylypchuk Ye.V., Petranovskaya A.L., Gorbyk P.P. Synthesis and Properties of Nanocomposites Based on Magnetite Modified with Diethylenetriamine Pentaacetic Acid. Nanostructures. Mater. Sci. 2012. (3): 47. [in Russian].

58. Petranovskaya A.L., Turelik M.P., Pylypchuk Ye.V. Nanocomposites on the basis of magnetite for medicine and pharmacy. In: Nanotechnology in pharmacy and medicine: International. conf. (Kharkiv, 2011). P. 154. [in Russian].

59. Turelik M.P., Gorobets S.V., Macedonskaya A.O., Gorbyk P.P. Biofunctionalisation of nanocomposites based on magnetite modified with meso-2,3-dimercaptosuccinic acid. Scientific. News of NTUU "KPI". 2012. (1): 149. [in Ukrainian].

60. Pylypchuk I.V., Kołodyńska D., Kozioł M., Gorbyk P.P. Gd-DTPA Adsorption on Chitosan/Magnetite Nanocomposites. Nanoscale Res. Lett. 2016. 11(1): 168. https://doi.org/10.1186/s11671-016-1363-3

61. Pylypchuk I.V., Kolodynska D., Gorbyk P.P. Gd(III) Adsorption on the DTPA-functionalized chitosan/magnetite nanocomposites. Sep. Sci. Technol. 2017: 1.

62. Pylypchuk Ye.V., Zubchuk Yu.O., Petranovskaya A.L., Turansky S.P., Gorbyk P.P. Synthesis and Properties of Fe3O4 Nanocomposites/ Hydroxyapatite/ Pamidronic Acid/ Diethylenetriamine Pentaacetic Acid/ Gd3+. Him. Fiz. Tehnol. Poverhni. 2015. 6(3): 326. [in Ukrainian]. https://doi.org/10.15407/hftp06.03.326

63. Hepatocellular carcinoma (HCC): a global perspective.

64. Maystrenko N.A., Sheiko S.B., Alent'ev A.V., Azimov F.K. Cholangiocellular cancer (features of diagnosis and treatment). Practical Oncology. 2008. 9(4): 229. [in Russian].

65. Kang T.W., Yevsa T., Woller N., Hoenicke L., Wuestefeld T., Dauch D., Hohmeyer A., Gereke M., Rudalska R., Potapova A., Iken M., Vucur M., Weiss S., Heikenwalder M., Khan S., Gil J., Bruder D., Manns M., Schirmacher P., Tacke F., Ott M., Luedde T., Longerich T., Kubicka S., Zender L. Senescence surveillance of pre-malignant hepatocytes limits liver cancer development. Nature. 2011. 479: 547. https://doi.org/10.1038/nature10599

66. Yevsa T., Kang T.W., Zender L. Immune surveillance of pre-cancerous senescent hepatocytes limits hepatocellular carcinoma development. Oncoimmunology. 2012. 1(3): 398. https://doi.org/10.4161/onci.19128

67. Dauch D., Rudalska R., Cossa G., Nault J.C., Kang T.W., Wuestefeld T., Hohmeyer A., Imbeaud S., Yevsa T., Hoenicke L., Pantsar T., Bozko P., Malek N.P., Longerich T., Laufer S., Poso A., Zucman-Rossi J., Eilers M., Zender L. A MYC-aurora kinase A protein complex represents an actionable drug target in p53-altered liver cancer. Nat. Med. 2016. 22(7): 744. https://doi.org/10.1038/nm.4107

68. Pylypchuk Ie.V., Gorbyk P.P., Petranovska A.L., Korduban O.M., Markovsky P.E., Ivasyshyn O.M. Formation of biomimetic hydroxyapatite coatings on the surface of titanium and Ti-containing alloys: Ti–6Al–4V and Ti–Zr–Nb. Surface Chemistry of Nanobiomaterials. Applications of Nanobiomaterials. 2016. 3: 193.

69. Pylypchuk Ye., Petranovskaya A., Gorbyk P., Korduban A., Markovsky P., Ivasishin O. Biomimetic Hydroxyapatite Growth on Functionalized Surfaces of Ti-6Al-4V and Ti-Zr-Nb Alloys. Nanoscale Res. Lett. 2015. 10: 338. https://doi.org/10.1186/s11671-015-1017-x

70. Pylypchuk Ye.V., Petranovska A.L., Turelyk M.P., Gorbyk P.P. Formation of Biomimetic Hydroxyapatite Coating on Titanium Plates. Mater. Sci. 2014. 20(3): 328.

71. Petranovskaya A.L., Turelyk M.P., Pylypchuk Ye.V., Gorbyk P.P., Korduban A.M., Ivasyshin O.M. Formation of biomimetic hydroxyapatite on the surface of titanium. Metallophysics and Newest Technologies. 2013. 35(11): 1567. [in Russian].

72. Pylypchuk Ye.V., Abramov M.V., Petranovska A.L., Turanska S.P., Budnyak T.M., Kusyak N.V., Gorbyk P.P. Multifunctional Magnetic Nanocomposites on the Base of Magnetite and Hydroxyapatite for Oncology Applications. Nanochemistry, Biotechnology, Nanomaterials, and Their Applications. Selected Proceedings of the 5th International Conference Nanotechnology and Nanomaterials (NANO 2017). (Aug. 23–26, 2017, Chernivtsi, Ukraine.). P. 35.

73. Patent UA 100210. Semko L.S., Gorbyk P.P., Khutorny S.V. Method for obtaining a magnetic laminate material. 2012. [in Ukrainian].

74. Patent UA 78448. Gorbyk P.P., Petranovska A.L., Abramov M.V., Turelyk M.P., Pylypchuk Ye.V., Vasilyeva O.A. Magnetic fluid. 2013. [in Ukrainian].

75. Patent UA 78473. Paton B.E., Gorbyk P.P., Petranovska A.L., Turelyk M.P. Abramov M.V., Vasiliev A.A., Chekhun V.F. Lukyanov N.Yu. Magnetic antitumor fluid. 2013. [in Ukrainian].

76. Antitumor nanocomposite "Feroplat". Access point: http://files.nas.gov.ua/NASDevelopmentsBook/PDF/0760.pdf

77. Certificate 46056. Gorbyk P.P., Petanovskaya A.L., Turelik M.P., Abramov M.V., Vasilieva O.A. TTR (temporary technological regulation) on the for the production of the substance "Magnetite". 2012. [in Ukrainian].

78. Certificate 58159. Gorbyk P.P., Abramov M.V., Petranovskaya A.L., Pylypchuk Ye.V., Vasilieva O.A. TTR (temporary technological regulations) for the production of magnetic liquid. 2015. [in Ukrainian].

79. Targeted comprehensive program of fundamental research "Nanostructural systems, nanomaterials, nanotechnologies". 2010. [in Ukrainian].

80. Gorbyk P.P., Gorobets S.V., Turelyk M.P., Chekhun V.P., Shpak A.P. Biofunctionalisation of nanomaterials and nanocomposites: teach. manual. (Kyiv: Naukova Dumka, 2011). [in Ukrainian].

81. Gorbyk P.P., Turelik M.P., Gorobets S.V., Gorobets O.Yu., Demyanenko I.V. Bio-functionalized nanomaterials and nanocomposites. Scientific fundamentals and directions of application, Electronic tutorial. 2013. [in Ukrainian].

82. Storozhuk L.P. Ph.D (Chem.) Thesis. (Kyiv, 2007). [in Ukrainian].

83. Turelik M.P. Ph.D (Chem.) Thesis. (Kyiv, 2012). [in Ukrainian].

84. Pylypchuk Ye.V. Ph.D (Chem.) Thesis. (Kyiv, 2013). [in Ukrainian].

85. Kaminsky O.M. Ph.D (Chem.) Thesis. (Kyiv, 2018). [in Ukrainian].

86. Kusyak A.P. Ph.D (Chem.) Thesis. (Kyiv, 2018). [in Ukrainian].

87. Uvarova I.V., Gorbyk P.P., Gorobets S.V., Ivashchenko O.A., Ulyanchenko N.V. Nanomaterials of medical appointment. (Kyiv: Naukova Dumka, 2014) [in Ukrainian].

88. Gorobets S.V., Gorobets O.Yu., Gorbyk P.P., Uvarova I.V. Functional bio- and nanomaterials of medical purpose. (Kyiv: Condor, 2018). [in Ukrainian].

Published
2019-01-13
How to Cite
Abramov, M. V., Petranovska, A. L., Pylypchuk, Y. V., Turanska, S. P., Opanashchuk, N. M., Kusyak, N. V., Gorobets, S. V., & Gorbyk, P. P. (2019). Magnetosensitive polyfunctional nanocomposites on the basis of magnetite and hydroxyapatite for their use in oncology. Surface, (10(25), 244-285. https://doi.org/10.15407/Surface.2018.10.245
Section
Medical and biological problems of surface